胆管癌miR-551b表达变化的临床意义及其靶基因生物信息学分析

Abstract
Figure/Table
References
Related Citation (12)

Download: PDF (950 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical significance of miR-551b expressions in cholangiocarcinoma and analyze the target gene of mir-551b by bioinformatics.Methods Seventy-eight patients with cholangiocarcinoma who underwent radical resection in our hospital between October 2014 and October 2018 were selected as the cholangiocarcinoma group while another 40 patients who underwent Roux-en-Y cholangiojejunostomy due to bile duct stones were selected as the control group.The expressions of miR-551 and cyclin D1 in cholangiocarcinoma and normal bile duct tissues were calculated and the overall survival (OS) of patients with cholangiocarcinoma was followed up.Results The expression of miR-551b in cholangiocarcinoma tissues was lower than that in normal bile duct tissues.The expression of miR-551b in cholangiocarcinoma tissues of patients with increased preoperative serum CA19-9 and CEA,in TNM stage Ⅲ,or with low-undifferentiated and microvascular invasion were significantly lower than that of patients with normal preoperative serum CA19-9 and CEA,in TNM stageⅠ-Ⅱ,or with medium-high differentiation and non-microvascular invasion.Compared with cholangiocarcinoma patients with high miR-551b expressions,the overall survival of patients with low expressions of miR-551b was significantly shortened.miR-551b targeted 1456-1462 and 1479-1486 bases of mRNA 3′UTR of CyclinD1 gene,and the expression level of CyclinD1 in cholangiocarcinoma was significantly higher than that in the normal bile duct and negatively correlated with the expression of miR-551b.Preoperative CA19-9,TNM stage,microvascular invasion,and expressions of miR-551b and cyclinD1 were factors that influenced the overall survival of patients with cholangiocarcinoma.Conclusions The decrease of miR-551 expression in cholangiocarcinoma is related to the deterioration of pathological features and the shortening of total survival time.Targeting CyclinD1 is a possible mechanism by which miR-551 is involved in the occurrence and development of cholangiocarcinoma.

Key words： cholangiocarcinoma mir-551b cyclinD1 target gene bioinformatics

Received: 04 July 2020

ZTFLH:

R735.8

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Xueting
	CAI Jun
	SUN Yanjun
	SUN Dengqun

Cite this article:

LIU Xueting,CAI Jun,SUN Yanjun等. Clinical significance of miR-551b expression in cholangiocarcinoma and bioinformatics analysis of its target gene[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2020, 31(11): 964-968.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2020/V31/I11/964

[1]	Liu H,Cen X,Suo T,et al.Trends and hospital variations in surgical outcomes for cholangiocarcinoma in New York State[J].World J Surg,2017,41(2):525-537.
[2]	Chang W W,Hsiao P K,Qin L,et al.Treatment outcomes for unresectable intrahepatic cholangiocarcinoma:Nationwide,population-based,cohort study based on propensity score matching with the Mahalanobis metric[J].Radiother Oncol,2018,129(2):284-292.
[3]	Zhou M,Zhu Y,Hou R,et al.Identification of candidate genes for the diagnosis and treatment of cholangiocarcinoma using a bioinformatics approach [J].Oncol Lett,2019,18(5):5459-5467.
[4]	Wang J,Xu M X,Wang L Q,et al.Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma[J].J Biol Regul Homeost Agents,2019,33(5):1551-1557.
[5]	Li S,Chai Y,Ding Y,et al.CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma[J].Oncol Rep,2019,42(2):657-669.
[6]	Xu L,Wang L,Zhou L,et al.The SIRT2/cMYC pathway inhibits peroxidation-related apoptosis in cholangiocarcinoma through metabolic reprogramming [J].Neoplasia,2019,21(5):429-441.
[7]	Chang W,Wang Y,Li W,et al.MicroRNA-551b-3p inhibits tumour growth of human cholangiocarcinoma by targeting Cyclin D1[J].J Cell Mol Med,2019,23(8):4945-4954.
[8]	Adeva J,Sangro B,Salati M,et al.Medical treatment for cholangiocarcinoma[J].Liver Int,2019,39(Suppl 1):123-142.
[9]	Lin P,Zhong X Z,Wang X D,et al.Survival analysis of genome-wide profiles coupled with connectivity map database mining to identify potential therapeutic targets for cholangiocarcinoma[J].Oncol Rep,2018,40(6):3189-3198.
[10]	宗源,周军,沈琳.晚期胆管癌的药物治疗现状[J].中华临床医师杂志(电子版),2019,13(3):214-220.
[11]	Lukic A D I,Properzio M,Carico E,et al.MicroRNA-551b expression profile in low and high-grade cervical intraepithelial neoplasia [J].Eur Rev Med Pharmacol Sci,2018,22(14):4448-4457.
[12]	Wang Y,Fan X,Xu F,et al.Expression of miR-551b and its effect on apoptosis in human gastric carcinoma[J].Int J Clin Exp Pathol,2018,11(5):2912-2919.
[13]	Sun H Y,Qu Z C,Liu D M,et al.Decreased expression of miR-551b predicts poor prognosis and promotes tumorigenesis by targeting PTP4A3 in human colorectal cancer [J].Eur Rev Med Pharmacol Sci,2019,23(13):5741-5751.
[14]	Sittithumcharee G,Suppramote O,Vaeteewoottacharn K,et al.Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity[J].Hepatology,2019,70(5):1614-1630.
[15]	田立斌,张海光,鲁鑫,等.淋巴增强因子1及细胞周期蛋白D1在肝门部胆管癌中的表达及其临床意义[J].临床与病理杂志,2018,38(5):942-946.